Clinical Investigation for the Preview® hCG Urine/Serum Combo Pregnancy Test

NCT ID: NCT04207554

Last Updated: 2021-01-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

132 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-05

Study Completion Date

2020-12-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the agreement of the test device (Preview® hCG Urine/Serum Combo Pregnancy Test) with the predicate device, the QuickVue+ hCG Combo Test.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnancy Positive

Pregnant subjects within 11 weeks since the first day of last period.

Test Device-Strip Format

Intervention Type DEVICE

Sponsor's investigational device

Test Device-Cassette Format

Intervention Type DEVICE

Sponsor's investigational device

Predicate Device

Intervention Type DEVICE

Commercially available device

Pregnancy Negative

Non-pregnant subjects.

Test Device-Strip Format

Intervention Type DEVICE

Sponsor's investigational device

Test Device-Cassette Format

Intervention Type DEVICE

Sponsor's investigational device

Predicate Device

Intervention Type DEVICE

Commercially available device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Test Device-Strip Format

Sponsor's investigational device

Intervention Type DEVICE

Test Device-Cassette Format

Sponsor's investigational device

Intervention Type DEVICE

Predicate Device

Commercially available device

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Preview® hCG Urine/Serum Combo Pregnancy Test-Strip Format Preview® hCG Urine/Serum Combo Pregnancy Test-Cassette Format QuickVue+ hCG Combo Test

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adult women of childbearing age.
* Who either request a pregnancy test, or require a pregnancy test for diagnostic studies or treatment.
* Signed and dated informed consent.

Exclusion Criteria

* Minors.
* Adults who are unable to independently give consent for study.
* Known pregnancy (i.e. - patient appears obviously pregnant).
* Recent miscarriage or abortion and yet to have 2 complete menstrual cycles before study start.
* History of ectopic pregnancy, fibroids, congenital uterine anomaly that causes an irregular-shaped uterus.
* Taken any of the medications of contraceptives containing estrogen in last two weeks.
* Hemodynamically unstable.
* Moderately to severely ill-appearing or in moderate to severe pain.
* Technically not possible to obtain blood or urine from the study subject.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nova Clinical Solutions, Inc.

UNKNOWN

Sponsor Role collaborator

Guangzhou Wondfo Biotech Co., Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rui Liu, Master

Role: STUDY_CHAIR

Guangzhou Wondfo Biotech Co., Ltd

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Insitute of Clinical Research

Garden Grove, California, United States

Site Status

National Research Institute-Huntington Park

Huntington Park, California, United States

Site Status

Downtown L.A. Research Center, Inc

Los Angeles, California, United States

Site Status

National Research Institute-Westlake

Los Angeles, California, United States

Site Status

National Research Institute-Panorama City

Panorama City, California, United States

Site Status

National Research Institute-Santa Ana

Santa Ana, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

WIDE L, GEMZELL CA. An immunological pregnancy test. Acta Endocrinol (Copenh). 1960 Oct;35:261-7. doi: 10.1530/acta.0.xxxv0261. No abstract available.

Reference Type RESULT
PMID: 13785019 (View on PubMed)

Batzer FR. Hormonal evaluation of early pregnancy. Fertil Steril. 1980 Jul;34(1):1-13. doi: 10.1016/s0015-0282(16)44829-6. No abstract available.

Reference Type RESULT
PMID: 6995156 (View on PubMed)

Braunstein GD, Rasor J, Danzer H, Adler D, Wade ME. Serum human chorionic gonadotropin levels throughout normal pregnancy. Am J Obstet Gynecol. 1976 Nov 15;126(6):678-81. doi: 10.1016/0002-9378(76)90518-4.

Reference Type RESULT
PMID: 984142 (View on PubMed)

Braunstein GD, Vaitukaitis JL, Carbone PP, Ross GT. Ectopic production of human chorionic gonadotrophin by neoplasms. Ann Intern Med. 1973 Jan;78(1):39-45. doi: 10.7326/0003-4819-78-1-39. No abstract available.

Reference Type RESULT
PMID: 4734160 (View on PubMed)

Catt KJ, Dufau ML, Vaitukaitis JL. Appearance of hCG in pregnancy plasma following the initiation of implantation of the blastocyst. J Clin Endocrinol Metab. 1975 Mar;40(3):537-40. doi: 10.1210/jcem-40-3-537.

Reference Type RESULT
PMID: 1117063 (View on PubMed)

Lenton EA, Neal LM, Sulaiman R. Plasma concentrations of human chorionic gonadotropin from the time of implantation until the second week of pregnancy. Fertil Steril. 1982 Jun;37(6):773-8. doi: 10.1016/s0015-0282(16)46337-5.

Reference Type RESULT
PMID: 7115557 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WF2019-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Early PrEgnancy Complications Testing
NCT04079361 RECRUITING NA
Pregnancy Tracking Pilot
NCT04025892 WITHDRAWN NA